glp 1 weight loss maintenance What happens when you finally reach your goal weight? 🤔 For many people using GLP-1 medications, the journey doesn't end there. is a whole new chapter, and the goal shifts from Long-term Success of GLP-1s Hinges

doi:10.3390/antibiotics11020225 Ye D, Li X, Zhao L, et al

Mechanism of Action Tirzepatide: Dual incretin (GIP + GLP-1) enhanced metabolic impact Wegovy: GLP-1 receptor agonist now with higher receptor engagement Weight Loss Outcomes Tirzepatide: ~22% weight reduction in trials Wegovy 7.2 mg: ~2021% weight reduction The efficacy gap is narrowing significantly Cardiometabolic Profile Wegovy: Strong, established cardiovascular outcome data Tirzepatide: Superior glycemic control and insulin sensitivity Safety & Tolerability Both therapies show dose-dependent GI side effects Overall safety profiles remain comparable The Big Picture We are witnessing a shift from: Single-hormone optimization (high-dose semaglutide) to Multi-hormone targeting (tirzepatide) Conclusion While Wegovy is rapidly closing the efficacy gap with dose escalation, Tirzepatide continues to lead as a next-generation metabolic therapy

Discontinue use if unusual symptoms occur

The arrangement of the transmembrane helices reveals hallmarks of an active conformation similar to that observed in class A receptors

By modulating immune responses, glutathione promotes immune system balance and overall health